SLC5A2 and type 2 diabetes mellitus: The mean age of patients was 56.1 years, 34.5% were female, and all trials (excluding 1 with healthy volunteers) were in people with type 2 diabetes mellitus (T2DM) and studied high-dose SGLT-2 inhibitors (S1 Table).